Trastuzumab Active Not Recruiting Phase 2 Trials for Adenocarcinomas of the Gastroesophageal Junction Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03368131Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ´╝îIII of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma´╝Ü A Randomized, Controlled Clinical Study